Haleon plc HLN

Excedrin today announced My Little Headache, a digital pet experience inspired by the resurgence of nostalgic virtual pets, bringing the real-life chaos of a headache to life while introducing Excedrin Rapid Relief. The new product features patented Fast Release Technology and starts providing relief from tough pain in as little as 15 minutes, all in an aspirin-free and caffeine-free formula.

Big Tech is pouring an estimated $700b into AI infrastructure this year, and global healthcare is a key proving ground for whether that spend pays off. UK investors are watching closely because hospitals, drug makers and software providers that can turn AI into real efficiency gains may reshape healthcare economics. This article highlights three AI focused healthcare stocks from our screener to help you evaluate the landscape early. The stocks highlighted below are just a small sample of the...

Goldman Sachs handpicks European stocks with the highest conviction for outperformance, and four of October's top selections carry a benefit most growth-focused investors overlook entirely.

Rising UK government bond yields have pushed up borrowing costs and sharpened the focus on where future productivity gains might come from. Artificial intelligence in healthcare offers one clear answer. It aims to cut waste, speed up diagnosis and make treatment more precise, which can matter when capital is not cheap. This article highlights three transformative AI healthcare stocks that showcase how this theme is playing out in practice. The stocks covered below are just a small sample of...

Investing.com -- J.P. Morgan put “underweight” rated Haleon on negative Catalyst Watch ahead of its Oct. 29 results, saying third-quarter like-for-like sales growth is tracking at 3%, leaving the consumer health company at the bottom of its 3%-5% guidance range for a second straight year.

Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three...

Rising UK borrowing costs, highlighted by the recent jump in 10 year gilt yields ahead of the next budget, are forcing investors to think harder about where future growth could come from. That is one reason artificial intelligence in healthcare is getting more attention. This piece looks at three UK focused AI healthcare stocks from our screener that aim to tap into this shift and explains what each one offers. The three stocks covered below are just a sample, and the full screen surfaced 5...

Haleon plc (NYSE:HLN) is trying to win the US consumer-health market one shelf at a time. The Sensodyne and Advil owner has secured more prominent positions at Walmart Inc. (NYSE:WMT), Target Corporation (NYSE:TGT), and other major retailers by offering improved commercial terms, including lower prices, stronger promotions, new products, and exclusivity. READ ALSO: Keurig Dr […]

Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include...

Haleon plc (NYSE:HLN) is finding a new growth opportunity in the expanding U.S. population using GLP-1 weight-loss drugs such as Wegovy and Zepbound. According to Reuters, the company has been placing products that can address GLP-1-related side effects in both its normal store locations and dedicated GLP-1 sections at CVS. That strategy has produced an […]

The consumer health company’s GLP-1 shelf strategy at CVS is paying off, and bigger retailers could follow.

Up to 70% of GLP-1 patients experience gastrointestinal issues including nausea, vomiting, diarrhea, and constipation, per one study.

Shelf placement is becoming an increasingly important competitive weapon at Walmart Inc. (NYSE:WMT) and Target Corporation (NYSE:TGT). Haleon, the company behind Sensodyne, Advil, and Centrum, has negotiated more prominent positions at the two retailers by offering lower prices, stronger promotions, exclusive products, and other improved commercial terms. The strategy appears to be benefiting Haleon, whose […]

European consumer staples stocks are trading at 18-year lows relative to the broader market, yet Deutsche Bank expects the sector to continue to underperform as consumer spending fails to keep pace with nominal economic growth. Analyst Tom Sykes said the bank has repeatedly tested the...

With UK gilt yields responding to shifting Bank of England expectations, investors are rethinking where dependable long term growth could come from. Healthcare companies using artificial intelligence to improve diagnosis and treatment sit at the crossroads of technology and essential services, which can matter when borrowing costs and inflation concerns move in and out of focus. This article highlights three UK listed AI healthcare stocks from our screener to put on your radar. The stocks...